Journal of Dermatology and Dermatologic Diseases

Medical executive, Eris Lifesciences Ltd., Mumbai, Maharashtra, 400070, India

Publications

• Research Article   
  To evaluate real-world prescribing patterns, perceived effectiveness, safety, and combination practices of tofacitinib among Indian dermatologists
  Author(s): Manjunath Shenoy, Prakash C Bora, Shreya Poddar, Nisha Agrawal, T.N. Rekha Singh, Vijay S Joshi, Willem J Verberk and Shubhajit Paul*
  
  Background: Autoimmune skin diseases such as vitiligo, psoriasis, alopecia areata and atopic dermatitis cause substantial physical and psychosocial morbidity and durable remission remain challenging. The Janus kinase (JAK) pathway has emerged as a key therapeutic target, with tofacitinib-a JAK1/3 inhibitor offering a mechanism distinct from traditional immunosuppressant?s. Aims: To evaluate real-world prescribing patterns, perceived effectiveness, safety and combination practices of tofacitinib among Indian dermatologists. Methods: A cross-sectional, web-based survey (August-September 2024) of 825 Indian dermatologists used a validated 27-item questionnaire to assess prescribing trends, dosing, response timelines, adverse effects and management approaches. Results: Tofacitinib was most commonly prescribed for vitiligo and alopecia areata (97%), followed by psoriasis (93%) and .. Read More»
  

  Abstract PDF